{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:50:05Z","timestamp":1793677805490,"version":"4.5.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ejmech.2022.114187","type":"journal-article","created":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T02:21:48Z","timestamp":1644632508000},"page":"114187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in\u00a0vitro and in\u00a0vivo"],"prefix":"10.1016","volume":"232","author":[{"given":"Huachao","family":"Bin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinshan","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5147-3746","authenticated-orcid":false,"given":"Shengyong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114187_bib1","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: an essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2022.114187_bib2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1042\/BJ20102162","article-title":"ATR signalling: more than meeting at the fork","volume":"436","author":"Nam","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2022.114187_bib3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrc3916","article-title":"Replication stress and cancer","volume":"15","author":"Gaillard","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2022.114187_bib4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2217\/fon.15.292","article-title":"DNA replication stress and cancer: cause or cure?","volume":"12","author":"Taylor","year":"2016","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejmech.2022.114187_bib5","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.cub.2016.10.030","article-title":"RPA-binding protein ETAA1 is an ATR activator involved in DNA replication stress response","volume":"26","author":"Lee","year":"2016","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ejmech.2022.114187_bib6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","article-title":"Cell-cycle checkpoints and cancer","volume":"432","author":"Kastan","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114187_bib7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","article-title":"DNA replication stress as a hallmark of cancer","volume":"10","author":"Macheret","year":"2015","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ejmech.2022.114187_bib8","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114187_bib9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","article-title":"Targeting ATR in cancer","volume":"18","author":"Lecona","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2022.114187_bib10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/j.gastro.2021.03.022","article-title":"Sequential administration of XPO1 and ATR inhibitors enhances therapeutic response in TP53-mutated colorectal cancer","volume":"161","author":"Inoue","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2022.114187_bib11","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1126\/science.1140735","article-title":"An oncogene-induced DNA damage model for cancer development","volume":"319","author":"Halazonetis","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114187_bib12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/genetics\/31.3.269","article-title":"Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura","volume":"31","author":"Dobzhansky","year":"1946","journal-title":"Genetics"},{"key":"10.1016\/j.ejmech.2022.114187_bib13","doi-asserted-by":"crossref","first-page":"14151","DOI":"10.1021\/acs.jmedchem.0c00766","article-title":"Synthetic lethality through the lens of medicinal chemistry","volume":"63","author":"Myers","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114187_bib14","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.trecan.2018.09.007","article-title":"Synthetically lethal interactions of ATM, ATR, and DNA-PKcs","volume":"4","author":"Kantidze","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejmech.2022.114187_bib15","first-page":"4375","article-title":"Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin","volume":"58","author":"Sarkaria","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114187_bib16","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1039\/b504418a","article-title":"Chemistry and biology of wortmannin","volume":"3","author":"Wipf","year":"2005","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2022.114187_bib17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.cell.2006.03.035","article-title":"A\u00a0pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling","volume":"125","author":"Knight","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114187_bib18","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1093\/nar\/gkp593","article-title":"Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response","volume":"37","author":"Nishida","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2022.114187_bib19","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bjc.2011.243","article-title":"Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines","volume":"105","author":"Peasland","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114187_bib20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nsmb.2076","article-title":"A\u00a0cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations","volume":"18","author":"Toledo","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2022.114187_bib21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1021\/ml500352s","article-title":"Structure-based drug design of novel, potent, and selective azabenzimidazoles (ABI) as ATR inhibitors","volume":"6","author":"Barsanti","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114187_bib22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ygyno.2014.12.035","article-title":"Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells","volume":"136","author":"Teng","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejmech.2022.114187_bib23","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1021\/acs.jmedchem.9b00426","volume":"62","author":"Knegtel","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114187_bib24","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent","volume":"61","author":"Foote","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114187_bib25","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/acs.jmedchem.0c00369","article-title":"Damage incorporated: discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344 with favorable pharmacokinetic properties and promising efficacy in monotherapy and in combination treatments in preclinical tumor models","volume":"63","author":"L\u00fccking","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114187_bib26","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1021\/jm301859s","article-title":"Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in\u00a0vivo antitumor activity","volume":"56","author":"Foote","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114187_bib27","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114187_bib28","doi-asserted-by":"crossref","first-page":"107518","DOI":"10.1016\/j.pharmthera.2020.107518","article-title":"Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): clinical candidate for cancer therapy","volume":"210","author":"Gorecki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2022.114187_bib29","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114187_bib30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1541-7786.MCR-14-0240","article-title":"A\u00a0synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function","volume":"13","author":"Menezes","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114187_bib31","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","article-title":"AZD6738, A novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells","volume":"16","author":"Min","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114187_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/ijc.30373","article-title":"Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells","volume":"140","author":"Kim","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114187_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114187_bib34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/2159-8290.CD-20-1354","article-title":"ATR inhibition as an attractive therapeutic resource against cancer","volume":"11","author":"Italiano","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2022.114187_bib35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-Human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2022.114187_bib36","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3390\/ph3051311","article-title":"Prospects for the use of ATR inhibitors to treat cancer","volume":"3","author":"Wagner","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2022.114187_bib37","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ejmech.2015.04.037","article-title":"Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in\u00a0vitro and in\u00a0vivo","volume":"96","author":"Wang","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114187_bib38","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.bmcl.2011.10.104","article-title":"Ligand based design of novel histamine H\u2084 receptor antagonists; fragment optimization and analysis of binding kinetics","volume":"22","author":"Smits","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114187_bib39","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1016\/j.bmcl.2018.08.039","article-title":"Discovery and lead identification of quinazoline-based BRD4 inhibitors","volume":"28","author":"Yang","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114187_bib40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/cr.2017.158","article-title":"Cryo-EM structure of human ATR-ATRIP complex","volume":"28","author":"Rao","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2022.114187_bib41","doi-asserted-by":"crossref","first-page":"115863","DOI":"10.1016\/j.bmc.2020.115863","article-title":"Discovery of 2-(5-(quinolin-6-yl)-1,3,4-oxadiazol-2-yl)acetamide derivatives as novel PI3K\u03b1 inhibitors via docking-based virtual screening","volume":"29","author":"Gu","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114187_bib42","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.jmb.2017.04.006","article-title":"Rationally designed PI3K\u03b1 mutants to mimic ATR and their use to understand binding specificity of ATR inhibitors","volume":"429","author":"Lu","year":"2017","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2022.114187_bib43","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1126\/science.1184429","article-title":"Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34","volume":"327","author":"Miller","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114187_bib44","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/jm800295d","article-title":"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer","volume":"51","author":"Folkes","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114187_bib45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccell.2020.11.013","article-title":"Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site","volume":"39","author":"Chen","year":"2021","journal-title":"Cancer Cell"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422000897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422000897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:40:36Z","timestamp":1759329636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422000897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":45,"alternative-id":["S0223523422000897"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114187","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in\u00a0vitro and in\u00a0vivo","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114187"}}